Progress in science and technology have created the capabilities and alternatives to symptom-driven medical care. Reducing premature mortality associated with age-related chronic diseases, such as cancer and cardiovascular disease, is an urgent priority we address using advanced screening detection.
SIGNIFICANCE STATEMENT
Advances in science and technology have enabled scientists to analyze the human genome costeffectively and to combine genome sequencing with noninvasive imaging technologies for alternatives to symptom-driven medical care. Using whole genome sequencing and noninvasive 3D/4D imaging technologies we screened 209 adults to detect age-related chronic diseases, such as cancer and cardiovascular disease. We found unrecognized age-related chronic diseases requiring prompt (<30 days) medical attention in 1:12 study participants, likely genomic findings correlating with clinical data in 1:4 participants, and evidence of age-related chronic diseases or associated risk factors in more than 3 of 4 participants. These results demonstrate that genome sequencing with clinical imaging data can be used for screening and early detection of diseases associated with premature mortality.
INTRODUCTION
The near-doubling of average human life expectancy over the last 150 years is a tribute to scientific advancements in medicine and public health (1) . In large part this success is the result of progress in control and prevention of infectious diseases particularly among young children. Eight-five percent of children born now in the US can expect to live to 65 years of age; and 42% will likely celebrate an 85 th birthday (1) . As a result of this success the USA is facing a daunting and costly new medical challenge in the prevention (intervention) of age-related chronic diseases (1, 2) .
Most age-related chronic diseases have heritability (3, 4) , often are slowly progressive with symptom-free onset (5) , and are associated with common risk factors (2, 6) . In 2015, the estimated US cumulative mortality risk among males 50 to 74 years of age was 39%; for women, the risk was lower but still substantial at 24% (7) . The causes of these deaths are similar across genders with neoplasms and cardiovascular disease accounting for about one-third each. Diabetes and related conditions, respiratory, cirrhosis and other liver diseases, and neurologic disorders account for the remaining one-third.
Few published examples demonstrate how genomics (8, 9) might be proactively incorporated into new models for medical practice, and what infrastructure will be needed to support data generation and use (10) (11) (12) (13) (14) (15) . We employed noninvasive advanced phenotyping approaches to detect risk of disease prior to damaging medical events. We used pedigree information, clinical grade whole genome sequencing (9) ; global metabolomics (12, 16) ; 3D/4D imaging focusing on non-contrast whole-body magnetic resonance imaging (17) (18) (19) ; cardiac imaging; 2-week cardiac rhythm monitoring; and standard laboratory studies.
Our objective for active adults was similar to successful newborn screening using advanced mass spectroscopy technologies for early simultaneous detection of multiple life-threatening conditions (20, 21) . Age-related chronic diseases associated with premature mortality are much more common among active adults than diseases targeted in newborn screening which make them good candidates for screening, but requiring a broader set of specialized tools and technologies for identification of disease risk than a single modality such as DNA sequencing. Phenotype data enhances risk detection and clarifies ambiguous sequence information in N of 1 evaluations.
RESULTS
We enrolled 209 study participants, median age 55 yrs, range 20-98 yrs, 34.5% female, between September 10, 2015 and May 16, 2016 . Twenty-one (10%) of the 209 participants were from 7 families.
Selected characteristics comparing study participants to age and gender-adjusted NHANES cohort, a US population-based sample, is shown in Table 1 . Routine clinical laboratory testing was obtained on 90 study participants (43%); Quantose IR (including fasting blood glucose) was obtained on 208 participants and included fasting blood glucose. Magnetic resonance imaging-based quantitative body compartmentspecific fat and muscle estimation was conducted on 126 participants (60%). Some portion of the intended 2-week cardiac rhythm monitoring was completed on 140 (67%) participants; the median duration of monitoring was 5.9 days (range 0.8-14 days) ( Figure 1 ).
We identified seventeen study participants (8%) with evidence of age-related chronic diseases considered significant and highly actionable requiring prompt medical attention following confirmation of screening findings: four early stage neoplasias (thymoma, renal cell carcinoma, and two high grade prostate neoplasms), one enlarged aortic root, two newly recognized atrial fibrillation cases, two medically significant arrhythmias, one 3 rd degree heart block, one primary biliary cholangitis, and one xanthinuria ( Table 2) . Some individuals had no detectable genetic risk emphasizing the value of phenotyping technology. Table 3 lists the pathogenic associations of genomic variants. 52 (25%, 1:4) participants had likely mechanistic genotype-phenotype associations ( Figure 2 ). Of the 52 variants there were 34 unique genes, 38 unique variants, zygosity was 50 heterozygous and 2 homozygous, with 3 new variant-disease associations observed in 2 different families.
We identified 164 (78%, >3:4) participants with evidence of age-related chronic disease or risk factors.
One-hundred-and-eighteen study participants (56%) had evidence of diabetes or risk for diabetes: 15 (7%) had type 2 diabetes; 80 (38%) had pre-diabetes (38%), and 23 (11%) had insulin resistance (based on Quantose IR). Only 19 (16%) reported a history of type 2 diabetes or pre-diabetes ( Table 2) . Onehundred-and-twenty-four participants (59%) had evidence of atherosclerotic disease or risk. Thirty-three (16%) had evidence of metabolic syndrome. Twenty-eight participants (13%) met a screening definition for non-alcoholic fatty liver disease (NAFLD), and one had suspected non-alcoholic steatohepatitis (NASH). Many participants had multiple over-lapping conditions including: 29 with pre-diabetes and atherosclerotic disease or risk; 19 with pre-diabetes, atherosclerotic disease or risk, and metabolic syndrome and; 13 with insulin resistance and atherosclerotic disease or risk ( Figure 1 ). We identified 10 unique alleles in 14 subjects with metabolic signatures consistent with penetrance.
Metabolic pathways impacted by the allelic differences included fatty acid beta oxidation, fatty acid synthesis, urea cycle, and signatures associated with oxidative stress. Strong metabolic signatures were observed for two polymorphisms matching the genes' function. Two heterozygous ACADS variants, c.1510G>A and c.1030C>T, coding for the short-chain acyl-Coenzyme A dehydrogenase (SCAD) were detected in one case. In another case, the heterozygous ACADM variant c.1456C>T coding for mediumchain acyl-Coenzyme A dehydrogenase (MCAD) was detected and interestingly both enzymes participate in fatty acid beta-oxidation by reducing different fatty acid chain length (22) . SCAD specifically acts on the short chain fatty acid butyryl-CoA and MCAD reduces acyl-CoA chains containing 6-12 carbons. In the absence of SCAD activity, byproducts of butyryl-CoA including butyrycarnitine and ethylmalonate accumulate (23) . Greatly elevated levels of butyrylcarnitine and ethylmalonate (Z-scores above 97.5 th percentile) were observed in the plasma suggestive of combined metabolic penetrance of these variants.
Moreover, greatly elevated medium chain acyl-carnitines, hexanoylcarnitine, octanoylcarnitine and decanoylcarnitine (Z-scores above 97.5 the percentile) were detected suggestive of reduced MCAD activity. Large genome-wide association studies combined with metabolic profiling have previously identified associations between ACADS and MCAD and their respective metabolic substrates lending support to the metabolic penetrance observed on an individual basis in this study (24) (25) (26) . We previously reported on additional metabolomic/genetic variants which are heterozygotes for known recessively inherited disorders (12, 16) . These studies established that "carrier" disease state does not reflect carrier for individual metabolic variation. The number of adult cases of metabolic penetrance will continue to expanded using this approach.
Metabolomics analysis also detected xanthinuria in an individual with early onset (20's) recurrent renal stones (6 episodes) as well as the drug effect of xanthine oxidase inhibitors in 3 other individuals.
Although hypoxanthine and especially xanthine levels were elevated in both cases, normal urate and elevated orotate and orotidine levels, due to perturbed pyrimidine synthesis (27) , were only observed in individuals taking xanthine oxidase inhibitors (allopurinols) for their gout conditions.
DISCUSSION
We used a precision medicine screening approach integrating whole genome sequencing and phenotype assessments for disease risk detection among active adults focusing on age-related chronic diseases associated with premature mortality. We found a substantial burden of largely unrecognized disease risk among study participants using three different analytic perspectives including those: 1) with significant and highly actionable conditions requiring prompt medical attention for previously unrecognized potentially life-threatening age-related chronic diseases (8%); 2) with likely mechanistic genomic findings correlated with other clinical associations (25%) and; 3) with evidence of age-related chronic disease or risk factors (78%). In design of our study we hypothesized that by proactively combining clinical grade deep whole genome sequencing (9) , and advanced clinical testing including global metabolomics, as well as 3D/4D imaging, emphasizing use of radiation-free low-to-no risk technologies like non-contrast MRI and echocardiography, 2-week cardiac monitoring, as well as routine laboratory testing, we could identify more precise disease risks allowing for earlier intervention and better health outcomes. False positives and other negative aspects of screening were mitigated by the high prevalence and life-threatening nature of targeted conditions, use of low-to-no-risk technologies, and convergent approaches for interpretation of results. Our data supports clinical utility of the approach presently and sets a challenge for the future improvements, including decreasing costs, through use of supporting technologies and infrastructure.
There is warranted concern about testing performance whenever screening is undertaken in medical practice. False positives may expose people to unnecessary risks, anxiety, costs, and inconvenience (28) .
The traditional medical approach to minimizing false positives is to rely on occurrence of symptoms to increase pre-test probabilities, though this is poorly understood by most physicians (29) . Whole genome sequence data is a particular concern with the high number of VUS variants due to lack of N of 1 phenotype correlations. Traditional medical evaluations are clearly an inadequate approach for early recognition of age-related chronic diseases, many of which are preventable, and the fact that the later manifestations of these diseases now represent most of the current total US Medicare expenditure (2, 30) .
For nationally-sanctioned proactive single-disease adult screening programs, there are robust long-term evaluations examining testing performance in the context of clinical harms and benefits, and costsat the population level, even though it is now increasingly well recognized that individual risk varies widely for these conditions (31) . Both of these time-honored approaches have advanced health but are insufficient to cope with introduction of genomics and other new science and technologies (e.g., imaging and metabolomics) to medicine, particularly when combined with the dramatic demographic and epidemiologic changes underway in the US and globally. A major promise of genomics and precision medicine is to more tightly link curative (to identify pathology) and preventive (to identify risk) medical disciplines by creating new health and health care platforms to personalize disease risk and longitudinal care. Our data suggest a route to creating such an approach, initially focusing on prevention of premature deaths among active adults associated with age-related chronic diseases, then expanding to other causes of disability (e.g., disability-adjust life year, or DALY) and additional life stages.
Genomics as currently applied has been disappointing in its ability to unravel the "missing heritability" of most age-related chronic diseases, and other common diseases (32, 33) . This shortcoming is slowly improving as a result of public and private efforts to expand sequencing but still leaves a plethora of VUS to assess. All are dependent on heterogenous contributions to the public databases, not N of 1 studies.
First, we expect and are increasingly finding and seeing supporting evidence for the increasing recognition of rare variants with large effect sizes (3, 9, 34) . Combining this with advancements in monogenic and polygenic methodologies to assess causation including Mendelian randomization methods (35) , extension of genome-wide association study to create hazard models (36) , and continued exploration of pleiotropy (37), will increase clinical utility. Second, increasingly detailed mapping of molecular pathways and mechanisms associated with diseases and risk factors will provide a much needed improved capability to link genotype and phenotype data (12, 16, 38) . In our study, we were able to demonstrate the use of global metabolomics in mapping to genomic defects. This integration will strengthen with additional automation of analysis. Thirdly, we are working to quantitatively integrate genomics with other clinical data, particularly advanced imaging data, to create point-of-care clinical decision support (37, 39, 40) . The version of HLI Search TM we are using can query more than 40,000 genomes (individuals and families) and explore genotype-phenotype associations with millisecond response times.
We are expanding this capability using the full range of genome-and phenotype-derived data signals to rapidly identify, classify, and prioritize individual opportunities for tertiary (disease treatment), secondary (risk factor control), and primary prevention using human-and machine-driven feature extraction. Such will enable the practicing physician to incorporate precisions medicine toward disease prevention. The potential value of evolving medical practice from disease diagnosis to risk detection is supported by our study. A larger cohort and longer follow-up will strengthen these initial 209 case findings. The relatively high burden of risk identified may be partially due to self-selection of clients with health concerns. This is supported by comparison of our study participants to NHANES data (Table 2) , and has been suggested by earlier authors in similar studies (11) . We recommended follow-up imaging studies for slightly more than one-third of our study participants. Some of this is the nature of screening, which drives need for more definitive imaging studies better suited to specific abnormalities. Other instances of referral were intended to identify change over a specified time period which might be suggestive of cancer such as finding a cystic pancreatic lesion (41) or instability of a vascular lesion such an intracranial aneurysm (42) . In some instances, data is lacking to confidently predict the natural course of these findings, and as a result may cause unnecessary anxiety and unneeded surgery (41, 42) . However, the life-threatening consequences and relatively high prevalence of diseases associated with these lesions suggests that early recognition is likely to be beneficial for most individuals. Some of the technology used in this study has the potential to measure progression or resolution of the risk thus enhancing disease intervention.
Expansion of some or all of our approach reported here to broader populations will require attention to cost, utility, physician and consumer acceptance. We continue to explore additional innovative noninvasive phenotyping technologies in the search for N of 1 precision medicine.
MATERIALS AND METHODS
We enrolled active adults >18 years old (without acute illness, activity-limiting unexplained illness or symptoms, or known active cancer) able to come for 6-8 hours of on-site data collection, were able to undergo magnetic resonance imaging without sedation, in the case of women were not pregnant or attempting to become pregnant, and were interested in undergoing a novel precision medicine screening approach for disease risk detection including genomics and other testing, as part of an institutional review board-approved clinical research protocol. Study results were returned to study participants who were encouraged to involve their primary care physicians.
Participants underwent a verbal review of the institutional review board-approved consent (Western Institutional Review Board) and were given time to ask and receive answers to questions during a onehalf to one-hour sessions conducted by health professionals. Study participants underwent standardized activities related to data collection and return of results in pre-visit, visit, and post-visit phases during a 1-
year study period.
Selected data were collected regarding past medical and family history, risk factors, and medical symptoms prior to or during study participant visit (43) . Participants were instructed to stop taking supplements for 72 hours, and to fast after dinner the night before their morning appointment. On the day of visit, blood was obtained for whole genome sequencing (Human Longevity, Inc.)(9), global metabolomics (12) sequences and provides a platform for query of these variants with annotation data.
To identify potentially medically significant rare monogenic variants we used an internal version (release 0.27) of HLI Search TM in a two-step process: the first step focused on allele frequency <1% in the HLI cohort with annotation using ClinVar and HGMD as well as predicted loss of function variants; the second step focused on participant-specific phenotype-driven queries using an allele frequency of <1% based on family and individual medical history as well as abnormal clinical testing results.
Global metabolic profiling was performed using ultrahigh performance liquid-phase chromatography separation coupled with tandem mass spectrometry to assess the metabolic penetrance of the variants in these subject (44) . Z-scores were calculated for all metabolites in each subject against a reference cohort consisting of 42 fasted subjects of normal health, and metabolites with Z-scores below the 2.5 th or above the 97.5 th percentiles of the reference cohort were considered to be potentially indicative of metabolic abnormalities that warranted further investigation. Integration of metabolomic and gene sequence data Participants with likely mechanistic genomic findings correlating with clinical data were identified by expert review to identify convergent genomic and clinical (or phenotype) data relationships including at least two clinical (or phenotype) data elements supporting a genomic observation, including three generation family history and metabolite level correlation based on pathway mapping.
Baseline characteristics including reported past medical history for major categories of age-related chronic diseases by study participants were compared to responses from NHANES, a US populationbased cohort (Table 1) Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) > normal. The presence of any three of the following 5 criteria were considered to be evidence of metabolic syndrome: 1) visceral adipose tissue measured by MRI (post-processing by AMRA TM ) > 2SD above normal (19) , or android/gynoid fat measured by iDXA > normal; 2) triglycerides ≥150 mg/dL; 3) HDL cholesterol <40 mg/dL in men and <50 mg/dL in women or the participant is currently taking prescribed medicine for high cholesterol; 4) blood pressure ≥130/85 mmHg or the participant is currently taking prescription for hypertension; 5) Measured fasting glucose or hemoglobin A1c indicates pre-diabetes (48) or "borderline" in response to the question -Doctor told you have diabetes. The presence of non-alcoholic fatty liver disease or nonalcoholic steatohepatitis were considered likely if: for non-alcoholic fatty liver disease MRI-based estimate liver fat was <4% and did not have alcohol dependence, and for these individuals we used a formula including other demographic and laboratory data to identify likely non-alcoholic steatohepatitis (49) . 
Measured Systolic Blood Pressure
Median (25%-75%)
Measured LDL

Median (25%-75%)
Diseases
Neoplasms
Ever told you had cancer or malignancy
Cardiovascular
Ever told you had coronary heart disease
Chronic respiratory diseases
Ever told you had COPD?
Diabetes, urogenital, blood, and endocrine diseases
Doctor told you have diabetes
Cirrhosis and other chronic liver diseases
Ever told you had any liver condition
Neurological disorders
Blood relatives have Alzheimer's disease
Risk Factors
Alcohol use
Had at least 12 alcohol drinks/1 yr? The Global Burden of Disease benchmarks for health loss from death or disability was used to categorize our findings based on the leading causes of and/or risks for non-communicable death. 
